27 U.S. Cities Where Stocks Yield 26% a Year

What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

FDMT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.70%

Insider Buying (Last 12 Months): $13,600,000.00

Insider Selling (Last 12 Months): $1,727,789.96

4D Molecular Therapeutics Insider Trading History Chart

4D Molecular Therapeutics Share Price & Price History

^$18.36

▲ +0.28 (1.55%)

As of 06/2/2023 01:00 AM ET

Days: 30 | 90 | 365

27 U.S. Cities Where Stocks Yield 26% a Year

From Investing Daily | Ad

Get in on the action here.

4D Molecular Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/9/2023	Global Investors Lp Viking	Major Shareholder	Buy	850,000	$16.00	$13,600,000.00	4,787,914
4/21/2023	Jacob Chacko	Director	Sell	5,000	$20.05	$100,250.00
4/21/2023	Scott Bizily	Insider	Sell	3,750	$20.00	$75,000.00	2,109
3/1/2023	Scott Bizily	Insider	Sell	2,248	$19.30	$43,386.40	2,109
2/21/2023	David Kirn	CEO	Sell	17,997	$20.96	$377,217.12	1,875,602
1/19/2023	David Kirn	CEO	Sell	10,899	$20.03	$218,306.97	1,902,224
12/15/2022	David Kirn	CEO	Sell	32,933	$23.59	$776,889.47	1,967,067
12/1/2022	Scott Bizily	Insider	Sell	6,000	$22.79	$136,740.00	2,482
10/22/2021	David Schaffer	Director	Sell	1,900	$31.00	$58,900.00
10/20/2021	David Schaffer	Director	Sell	11,565	$31.02	$358,746.30
9/29/2021	David Schaffer	Director	Sell	16,871	$28.61	$482,679.31
9/27/2021	David Schaffer	Director	Sell	19,332	$32.89	$635,829.48

The Ultimate Passive Income Play

From The Oxford Club | Ad

The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.

Find Out What It Is Right Here.

>>>

SEC Filings (Institutional Ownership Changes) for 4D Molecular Therapeutics (NASDAQ:FDMT)

79.94% of 4D Molecular Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

4D Molecular Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/18/2023	New York State Common Retirement Fund	16,161	$0.28M	0.0%	-17.7%	0.049%
5/16/2023	State Street Corp	2,042,189	$35.11M	0.0%	+65.3%	6.343%
5/16/2023	Squarepoint Ops LLC	61,358	$1.06M	0.0%	-1.2%	0.191%
5/16/2023	Geode Capital Management LLC	577,922	$9.93M	0.0%	+2.9%	1.795%
5/16/2023	ArrowMark Colorado Holdings LLC	1,032,719	$17.75M	0.2%	+5.1%	3.208%
5/15/2023	Cubist Systematic Strategies LLC	1,815	$31K	0.0%	-88.7%	0.006%
5/15/2023	Two Sigma Advisers LP	100,000	$1.72M	0.0%	+352.5%	0.311%
5/15/2023	Two Sigma Investments LP	200,883	$3.45M	0.0%	+30.5%	0.624%
5/15/2023	Deutsche Bank AG	80,267	$1.38M	0.0%	+7.1%	0.249%
5/15/2023	Price T Rowe Associates Inc. MD	18,381	$0.32M	0.0%	+5.8%	0.057%
5/15/2023	Healthcare of Ontario Pension Plan Trust Fund	472,500	$8.12M	0.0%	-38.9%	1.468%
5/12/2023	Renaissance Technologies LLC	13,800	$0.24M	0.0%	-89.2%	0.043%
5/12/2023	Candriam S.C.A.	235,000	$3.72M	0.0%	N/A	0.730%
5/12/2023	BlackRock Inc.	2,550,735	$43.85M	0.0%	+1.7%	7.923%
5/12/2023	Sectoral Asset Management Inc.	80,029	$1.38M	0.3%	+48.7%	0.249%
5/12/2023	Bank of America Corp DE	192,883	$3.32M	0.0%	+149.2%	0.599%
5/12/2023	UBS Group AG	52,399	$0.90M	0.0%	+28.7%	0.163%
5/12/2023	Dimensional Fund Advisors LP	146,958	$2.53M	0.0%	N/A	0.456%
5/12/2023	Wellington Management Group LLP	175,516	$3.02M	0.0%	-32.7%	0.545%
5/12/2023	Charles Schwab Investment Management Inc.	218,106	$3.75M	0.0%	+0.6%	0.677%
5/12/2023	Profund Advisors LLC	25,079	$0.43M	0.0%	N/A	0.078%
5/11/2023	M&T Bank Corp	28,814	$0.50M	0.0%	+22.4%	0.089%
5/11/2023	FMR LLC	2,694	$46K	0.0%	-90.0%	0.008%
5/11/2023	Citigroup Inc.	111,678	$1.92M	0.0%	+332.6%	0.347%
5/10/2023	Credit Suisse AG	13,465	$0.23M	0.0%	+1,346,400.0%	0.042%
5/10/2023	Swiss National Bank	38,500	$0.66M	0.0%	N/A	0.120%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	48,799	$0.84M	0.0%	+1.2%	0.152%
5/9/2023	Tower Research Capital LLC TRC	8,366	$0.14M	0.0%	+124.4%	0.026%
5/9/2023	Bank of New York Mellon Corp	108,455	$1.86M	0.0%	-1.3%	0.337%
5/9/2023	California State Teachers Retirement System	26,808	$0.46M	0.0%	+123.8%	0.083%
5/4/2023	Barclays PLC	57,229	$0.98M	0.0%	+65.1%	0.178%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	19,824	$0.34M	0.0%	+34.5%	0.062%
5/2/2023	Amalgamated Bank	3,172	$55K	0.0%	-16.2%	0.010%
4/28/2023	SG Americas Securities LLC	6,275	$0.11M	0.0%	-27.3%	0.019%
4/12/2023	Vontobel Holding Ltd.	80,529	$1.38M	0.0%	+49.6%	0.242%
3/29/2023	Diametric Capital LP	15,554	$0.35M	0.2%	N/A	0.047%
2/16/2023	Alliancebernstein L.P.	17,100	$0.38M	0.0%	N/A	0.053%
2/15/2023	Jane Street Group LLC	36,306	$0.81M	0.0%	N/A	0.112%
2/15/2023	Lazard Asset Management LLC	2,179	$48K	0.0%	N/A	0.007%
2/15/2023	State of Wisconsin Investment Board	13,300	$0.30M	0.0%	-75.7%	0.041%
2/15/2023	Soleus Capital Management L.P.	254,700	$5.66M	0.8%	N/A	0.786%
2/15/2023	Squarepoint Ops LLC	62,126	$1.38M	0.0%	N/A	0.192%
2/15/2023	Laurion Capital Management LP	21,401	$0.48M	0.0%	-91.3%	0.066%
2/15/2023	Legal & General Group Plc	2,846	$63K	0.0%	-69.7%	0.009%
2/15/2023	Morgan Stanley	1,458,572	$32.40M	0.0%	-27.8%	4.503%
2/15/2023	Norges Bank	294,000	$6.53M	0.0%	N/A	0.908%
2/15/2023	Fred Alger Management LLC	6,241	$0.14M	0.0%	N/A	0.019%
2/15/2023	ArrowMark Colorado Holdings LLC	982,199	$21.82M	0.3%	-35.8%	3.032%
2/14/2023	Point72 Asset Management L.P.	139,300	$3.09M	0.0%	-53.4%	0.430%
2/14/2023	PDT Partners LLC	20,802	$0.46M	0.1%	+11.1%	0.064%
2/14/2023	Price T Rowe Associates Inc. MD	17,379	$0.39M	0.0%	-4.0%	0.054%
2/14/2023	Marshall Wace LLP	69,747	$1.55M	0.0%	N/A	0.215%
2/14/2023	Two Sigma Investments LP	153,974	$3.42M	0.0%	+836.1%	0.475%
2/13/2023	Charles Schwab Investment Management Inc.	216,900	$4.82M	0.0%	+2.8%	0.670%
2/13/2023	Deutsche Bank AG	74,969	$1.67M	0.0%	+2.2%	0.231%
2/13/2023	Peloton Wealth Strategists	37,000	$0.82M	0.4%	-27.5%	0.114%
2/13/2023	Barclays PLC	34,673	$0.77M	0.0%	+204.8%	0.107%
2/13/2023	Renaissance Technologies LLC	128,100	$2.85M	0.0%	+85.4%	0.395%
2/13/2023	The Manufacturers Life Insurance Company	12,024	$0.27M	0.0%	-4.7%	0.037%
2/13/2023	Geode Capital Management LLC	561,737	$12.48M	0.0%	+6.2%	1.734%
2/13/2023	JPMorgan Chase & Co.	439,974	$9.77M	0.0%	-2.9%	1.358%
2/10/2023	Opaleye Management Inc.	330,000	$7.33M	2.5%	-5.9%	1.019%
2/10/2023	Bank of America Corp DE	77,412	$1.72M	0.0%	+288.9%	0.239%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	48,198	$1.07M	0.0%	N/A	0.149%
2/10/2023	Sectoral Asset Management Inc.	53,836	$1.20M	0.2%	N/A	0.166%
2/10/2023	Advisor Group Holdings Inc.	1,699	$38K	0.0%	-70.3%	0.005%
2/9/2023	Mirae Asset Global Investments Co. Ltd.	14,740	$0.33M	0.0%	+17.4%	0.046%
2/9/2023	Denali Advisors LLC	2,000	$44K	0.0%	N/A	0.006%
2/9/2023	Citigroup Inc.	25,816	$0.57M	0.0%	+160.9%	0.080%
2/8/2023	UBS Group AG	40,728	$0.91M	0.0%	N/A	0.126%
2/8/2023	Belpointe Asset Management LLC	1,671	$37K	0.0%	N/A	0.005%
2/7/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	12,036	$0.25M	0.0%	N/A	0.037%
2/2/2023	SG Americas Securities LLC	8,631	$0.19M	0.0%	-59.4%	0.027%
1/23/2023	Allspring Global Investments Holdings LLC	12,758	$0.28M	0.0%	-39.1%	0.039%
12/13/2022	Perigon Wealth Management LLC	250,475	$2.01M	0.2%	-28.2%	0.773%
12/8/2022	Bank of New York Mellon Corp	107,217	$0.86M	0.0%	+9.6%	0.331%
11/21/2022	California State Teachers Retirement System	35,469	$0.29M	0.0%	-1.7%	0.110%
11/17/2022	M&T Bank Corp	58,256	$0.47M	0.0%	+14.0%	0.180%
11/16/2022	Balyasny Asset Management LLC	37,044	$0.30M	0.0%	N/A	0.114%
11/15/2022	State Street Corp	677,176	$5.44M	0.0%	+7.1%	2.091%
11/15/2022	Two Sigma Investments LP	16,449	$0.13M	0.0%	-64.2%	0.051%
11/15/2022	Trexquant Investment LP	25,118	$0.20M	0.0%	-50.5%	0.078%
11/15/2022	UBS Asset Management Americas Inc.	26,894	$0.22M	0.0%	+104.0%	0.083%
11/15/2022	Vanguard Group Inc.	1,320,362	$10.62M	0.0%	-0.1%	4.076%
11/15/2022	Price T Rowe Associates Inc. MD	18,108	$0.15M	0.0%	+14.7%	0.056%
11/15/2022	Peloton Wealth Strategists	51,000	$0.41M	0.2%	+66.6%	0.157%
11/15/2022	Ensign Peak Advisors Inc	7,180	$58K	0.0%	+167.9%	0.022%
11/15/2022	Bank of New York Mellon Corp	107,217	$0.86M	0.0%	+9.6%	0.331%
11/15/2022	BlackRock Inc.	2,230,399	$17.93M	0.0%	+2.2%	6.886%
11/14/2022	Point72 Asset Management L.P.	299,000	$2.40M	0.0%	N/A	0.923%
11/14/2022	PDT Partners LLC	18,719	$0.15M	0.0%	N/A	0.058%
11/14/2022	Renaissance Technologies LLC	69,100	$0.56M	0.0%	-73.4%	0.213%
11/10/2022	Tower Research Capital LLC TRC	4,401	$35K	0.0%	-36.2%	0.014%
11/8/2022	New York State Common Retirement Fund	19,661	$0.16M	0.0%	+102.6%	0.061%
11/3/2022	Barclays PLC	11,376	$91K	0.0%	+18.3%	0.035%
10/31/2022	SG Americas Securities LLC	21,237	$0.17M	0.0%	+38.7%	0.066%
10/26/2022	Allspring Global Investments Holdings LLC	20,948	$0.17M	0.0%	N/A	0.065%
8/19/2022	Walleye Capital LLC	28,068	$0.20M	0.0%	N/A	0.087%
8/18/2022	Goldman Sachs Group Inc.	133,563	$0.93M	0.0%	+77.0%	0.412%
8/16/2022	Price T Rowe Associates Inc. MD	15,790	$0.11M	0.0%	+38.8%	0.049%

Data available starting January 2016

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Today's Range

Now: $18.36

$17.78

$18.51

50 Day Range

MA: $17.73

$15.16

$21.81

52 Week Range

Now: $18.36

$5.32

$26.49

Volume

394,143 shs

Average Volume

624,473 shs

Market Capitalization

$610.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.51

Who are the company insiders with the largest holdings of 4D Molecular Therapeutics?: 4D Molecular Therapeutics' top insider shareholders include:
Global Investors Lp Viking (Major Shareholder)
David Kirn (CEO)
Scott Bizily (Insider)
David Schaffer (Director)
Jacob Chacko (Director)
Learn More about top insider investors at 4D Molecular Therapeutics.
Who are the major institutional investors of 4D Molecular Therapeutics?: 4D Molecular Therapeutics' top institutional shareholders include:
BlackRock Inc. — 7.92%
State Street Corp — 6.34%
ArrowMark Colorado Holdings LLC — 3.21%
Geode Capital Management LLC — 1.80%
Healthcare of Ontario Pension Plan Trust Fund — 1.47%
Candriam S.C.A. — 0.73%
Learn More about top institutional investors of 4D Molecular Therapeutics stock.
Which institutional investors are selling 4D Molecular Therapeutics stock?: During the previous quarter, FDMT stock was sold by these institutional investors:
Healthcare of Ontario Pension Plan Trust Fund
Renaissance Technologies LLC
Wellington Management Group LLP
FMR LLC
Cubist Systematic Strategies LLC
New York State Common Retirement Fund
SG Americas Securities LLC
Bank of New York Mellon Corp
During the previous year, company insiders that have sold 4D Molecular Therapeutics company stock include:
Global Investors Lp Viking (Major Shareholder)
David Kirn (CEO)
Scott Bizily (Insider)
Learn More investors selling 4D Molecular Therapeutics stock.
Which institutional investors are buying 4D Molecular Therapeutics stock?: Within the last quarter, FDMT stock was bought by institutional investors including:
State Street Corp
Candriam S.C.A.
Dimensional Fund Advisors LP
Bank of America Corp DE
Citigroup Inc.
Two Sigma Advisers LP
Susquehanna International Group LLP
ArrowMark Colorado Holdings LLC